TAVI 30 day Mortality Calculator





Predicted 30 Day Mortality

Following TAVI








This model can only provide an estimate of the mortality risk. The precision of the estimate will be less good for cases that involve a combination of factors that is less frequently encountered

The model has not been validated for clinical decision support



Pulmonary disease: Chronic Obstructive Airways Disease / Emphysema: Patient requires medication (inhalers, aminophylline or steroids) for chronic pulmonary disease or FEV1 less than 75% predicted value. Venous pO2 < 60mmHg, pCO2 > 50mmHg. Asthma. Intermittent or allergic reversible airways disease treated with bronchodilators or steroids, or other significant pulmonary disease

Extracardiac arteriopathy: History or evidence of aneurysm or occlusive peripheral vascular disease or carotid disease, including aortic aneurysm, previous aorto-iliac or peripheral vascular surgery, or reduced or absent peripheral pulses and/or angiographic stenosis of more than 50%. Include femoral or carotid bruits as evidence of peripheral vascular disease.

Critical pre-operative status: Any of the following options: ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anaesthetic room, preoperative inotropes or IABP, preoperative acute renal failure (anuria or oliguria <10ml/hr)

Poor mobility: severe impairment of mobility secondary to musculoskeletal or neurological dysfunction

KATZ: Index 0 to 6

Non Elective procedure: Patient not admitted from routine waiting list for TAVI


Programming by Peter Ludman 2017

peter.ludman@uhb.nhs.uk


Based on risk model from:

Martin GP, Sperrin M, Ludman PF, de Belder MA, Redwood SR, Townend JN, Gunning M, Moat NE, Banning AP, Buchan I, Mamas MA. Novel United Kingdom prognostic model for 30-day mortality following transcatheter aortic valve implantation. Heart 2017

Link to download publication

Patients treated by TAVI in the UK from 2009 to 2014 were included in the creation and testing of this risk prediction model.

The model is well calibrated, but in common with all other existing models it only shows moderate discrimination.

The risk mortality estimate is therefore recommended to be used for guidance in the overall discussion about TAVI but not as a recommendation for or against any intervention



Disclaimer

Use at entirely your own risk


The model is well calibrated, but in common with all other existing models it only shows moderate discrimination.

The risk mortality estimate is therefore recommended to be used for guidance in the overall discussion about TAVI but not as a recommendation for or against any intervention

This model can only provide an estimate of the mortality risk. The precision of the estimate will be less good for cases that involve a combination of factors that is less frequently encountered

The model has not been validated for clinical decision support